Abstract
CEA is the marker of choice for colorectal cancers. Present data for others markers are insufficient to determine their real usefulness. An elevated CEA at the time of diagnosis is considered of a bad prognosis but CEA is not used for decision of treating patient with adjuvant therapy. The role of CEA in monitoring the treatments is still limited in part because the studies of the kinetic parameters of the marker during chemotherapy are not generalized. CEA is an excellent test for the follow-up of treated patients, enhancing the chances of detecting the relapses when they are curable. CA 19-9 is of limited use for the early diagnosis of pancreatic carcinoma, it is of predictive value for response and prognosis in patients undergoing chemotherapy or radiochemotherapy. AFP is an accurate biological parameter in screening for hepatocarcinoma in patients with cirrhosis. AFP has no utility in patients with non cirrhotic hepatitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
